No Data
Agios Pharmaceuticals Announced It Will Present New Data And Results From Its Phase 3 Study On AG-946 At The 66th American Society Of Hematology Annual Meeting In San Diego, California From December 7-10, 2024
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank
No Data
No Data